Contents

Search

abrocitinib (Cibinqo)

Indications: - atopic dermatitis Dosage: - 100-200 mg PO QD Adverse effects: - nausea (11%) - acne (7%) * dose-dependent (% for 200 mg dose) Mechanism of action: - Janus kinase 1 (JAK1) inhibitor - reduces interleukin-4 & interleukin-13 signaling

General

small inhibitory antineoplastic agent (ib drug)

Database Correlations

PUBCHEM cid=78323835

References

  1. Bieber T, Simpson EL, Silverberg JT et al Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med 2021; 384:1101-1112. March 25 PMID: 33761207 https://www.nejm.org/doi/full/10.1056/NEJMoa2019380
  2. Highlights of Prescribing Information CIBINQO (abrocitinib) tablets, for oral use https://labeling.pfizer.com/ShowLabeling.aspx?id=16652